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ABSTRACT 79 
Background 80 
More than ten years have elapsed since human papillomavirus (HPV) vaccination was implemented. We performed a 81 
systematic review and meta-analysis of the population-level impact of female-only HPV vaccination on HPV infections, 82 
anogenital wart diagnoses (AGW) and cervical intraepithelial neoplasia grade 2+ (CIN2+) to summarise the most recent 83 
evidence about the effectiveness of HPV vaccines in real-world settings and to quantify the impact of multiple age-cohort 84 
vaccination. 85 
 86 
Methods 87 
We updated our prior review (01/01/2007–28/02/2014), by searching Medline and Embase (01/02/2014–11/10/2018) for 88 
studies that examined changes, between pre- and post-vaccination periods, in HPV infections, AGW, or CIN2+. We 89 
stratified all analyses by sex, age, and years since HPV vaccination introduction. We used random-effects models to 90 
estimate pooled relative risks and performed subgroup analysis to identify the main sources of heterogeneity.  91 
 92 
Findings 93 
We identified 65 eligible articles conducted in 14 high-income countries. After 5-8 years of vaccination, HPV-16/18, AGW, 94 
and CIN2+ decreased significantly by about 80%, 70%, and 50% among girls aged 15-19 years and by 65%, 55%, and 30% 95 
among women aged 20-24 years. Significant cross-protection and herd effects were also observed. HPV-31/33/45 decreased 96 
significantly by 50% among girls aged 15-19 years and AGW decreased significantly by 30-50% among boys/men aged 15-97 
24 years. After 5-8 years of vaccination, countries with multi-cohort vaccination and high coverage (≥50%) had greater 98 
reductions in AGW, 44 and 85 percentage points among girls and boys aged 15-19 years, respectively, than countries with 99 
single-cohort vaccination and/or low vaccination coverage.  100 
 101 
Interpretation 102 
Our meta-analysis, including data from >60 million individuals from 14 high-income countries, shows a substantial impact 103 
of female-only HPV vaccination programs on AGW among girls/women and boys/men, and HPV infections and CIN2+ 104 
among girls/women. In addition, programs with multi-cohort vaccination and high vaccination coverage lead to greater and 105 
faster direct impact and herd effects. 106 
 107 
Funding 108 
World Health Organization, The Canadian Institute of Health Research, and the Fonds de recherche du Québec - Santé 109 
(FRQS)  110 
  111 
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RESEARCH INTO CONTEXT  112 
 113 
Evidence before this study 114 
Since 2007, 99 countries and territories have introduced HPV vaccination programs.  In 2015, we conducted a systematic 115 
review and meta-analysis to examine the real-world population-level impact of HPV vaccination. The meta-analysis showed 116 
substantial decreases in HPV-16/18 infections and anogenital wart diagnoses among females targeted for vaccination, and 117 
evidence of herd effects among boys and older women, 4 years after the introduction of HPV vaccination. However, at the 118 
time of the meta-analysis, the number of years post-vaccination was insufficient to examine the impact of HPV vaccination 119 
on cervical intraepithelial neoplasia grade 2+ (CIN2+). Moreover, in 2016, the World Health Organization (WHO) Strategic 120 
Advisory Group of Experts on Immunization revised its position to recommend HPV vaccination of multiple age cohorts of 121 
girls, rather than vaccinating a single cohort.  122 
 123 
We updated our previous systematic review to 1) summarise the most recent evidence about the impact of HPV vaccination 124 
on HPV infections and anogenital wart diagnoses, 2) summarise new evidence about the impact of HPV vaccination on 125 
CIN2+, and 3) compare the impact between countries having implemented either a single or multiple age cohort vaccination 126 
strategy. To do so, we searched Medline and Embase (Feb 1, 2014 and October 11, 2018), without language restriction, with 127 
terms including  (“papillomavirus vaccine”, “papillomavirus vaccination”, “HPV vaccine”, or “HPV vaccination”) and 128 
(“program evaluation”, “population surveillance”, “sentinel surveillance”, “incidence”, or prevalence”), and 129 
(“papillomavirus infection”, “condylomata acuminata”, “anogenital warts”, “cervical intraepithelial neoplasia”, “cervical 130 
dysplasia”, “uterine cervical neoplasm”, or “HPV related diseases”). We identified 47 new eligible articles added to our first 131 
review for a total of 65 articles. We contacted all corresponding authors of eligible studies to request a re-analysis of their 132 
data using the same data stratification to allow comparison between studies and pooling. 133 
 134 
Added value of this study 135 
The current updated systematic review and meta-analysis, which includes data from 60 million individuals and up to 8 years 136 
of post-vaccination follow-up, shows compelling evidence of the substantial impact of HPV vaccination programs on HPV 137 
infections, anogenital wart diagnoses and CIN2+ among women, and herd effects among boys and older women. Our study 138 
also shows greater and faster direct impact and herd effects in countries with multiple age cohort vaccination and high 139 
vaccination coverage compared to countries with single age-cohort vaccination or low routine vaccination coverage.  140 
Our study is the first: 1) to present pooled estimates of the population-level impact of HPV vaccination on CIN2+, the most 141 
proximal outcome to cervical cancer recognized as a valid proxy for vaccine efficacy against cervical cancer, and 2) to show 142 
the real-world additional benefit of vaccinating multiple age cohorts of girls with high vaccination coverage.   143 
 144 
Implication of all available evidence 145 
Our results are the strongest yet that HPV vaccination is working to prevent cervical cancer in real-world settings, as both 146 
the cause (high-risk HPV infection) and proximal disease endpoints are significantly declining. In terms of global policy 147 
implications, these results reinforce the recently revised position of the WHO recommending HPV vaccination of multiple 148 
age cohorts of girls and are promising early signs that the WHO call for action on cervical cancer elimination may be 149 
possible if sufficient population-level vaccination coverage can be reached.  150 
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INTRODUCTION 151 
More than ten years after the licensure of the first human papillomavirus (HPV) vaccines, 99 countries and territories have 152 
introduced HPV vaccination programs.1, 2 Observational data showing the population-level impact of HPV vaccination from 153 
the early adopting countries can be immensely useful for decision makers examining whether to introduce or modify HPV 154 
vaccination programs. This is because such data demonstrate the effectiveness of HPV vaccines in real-world settings and 155 
can assist in the identification of the program characteristics that lead to the greatest reductions in HPV-related infections 156 
and diseases.  157 
 158 
In 2015, we conducted a systematic review and meta-analysis of the population-level impact of HPV vaccination, including 159 
data from nine high-income countries up to four years after the introduction of HPV vaccination.3 Our meta-analysis 160 
showed substantial decreases in HPV-16/18 infections and anogenital wart diagnoses among girls and young women 161 
targeted for vaccination. Furthermore, in countries with high vaccination coverage (≥ 50%), there was evidence of vaccine 162 
cross-protection and herd effects, with statistically significant reductions in HPV-31/33/45 infection among girls targeted 163 
for vaccination and anogenital wart diagnoses among unvaccinated boys and older women, respectively. However, in this 164 
previous meta-analysis, the number of years post-vaccination was insufficient to examine the impact of HPV vaccination on 165 
the occurrence of cervical intraepithelial neoplasia grade 2+ (CIN2+), the most proximal outcome for cervical cancer.4 166 
 167 
In this paper, we update our systematic review and meta-analysis for three main reasons. Firstly, the number of countries 168 
and studies reporting observational data of the population-level impact of HPV vaccination has increased dramatically since 169 
our first review, which will improve both the power and generalizability of results. Secondly, the number of years post-170 
vaccination has increased, which allows analysis of changes in CIN2+ since the introduction of HPV vaccination. Thirdly, 171 
the World Health Organization’s (WHO) Strategic Advisory Group of Experts on Immunization revised its position in 2016 172 
to recommend HPV vaccination of multiple age cohorts of girls when introducing the vaccine in a country, rather than 173 
vaccinating a single age cohort.5 Prior to this recommendation, some high-income countries had implemented multiple age-174 
cohort vaccination, mainly through catch-up campaigns. A better understanding of the population-level impact of multiple 175 
age-cohort vaccination will help inform policy-makers’ decisions regarding whether to follow the recent WHO 176 
recommendation.  177 
 178 
Thus, the aims of this systematic review and meta-analysis are to: 1) update and summarise the most recent evidence about 179 
the population-level impact of girls-only HPV vaccination on HPV infections and anogenital wart diagnoses among girls, 180 
women, boys and men, 2) summarise new evidence about the population-level impact of girls-only HPV vaccination on 181 
CIN2+ occurrence among screened girls/women, and 3) compare the population-level impact of HPV vaccination on 182 
anogenital wart diagnoses and CIN2+ between countries having implemented either a single or a multiple age-cohort 183 
vaccination strategy. 184 
 185 
METHODS 186 
Search strategy and selection of articles 187 
In this updated systematic review, we used the same search strategy as our previous paper3 and report our methods in 188 
accordance with the PRISMA guidelines (Appendix Table S1).6 Briefly, studies were eligible if they compared the 189 
frequency (prevalence or incidence) of at least one HPV-related endpoint: 1) genital HPV infections, 2) anogenital wart 190 
diagnoses, or 3) histologically confirmed CIN2+, between the pre- and post-vaccination periods, among the general 191 
population and using the same population sources and recruitment methods pre- and post-vaccination. For CIN2+, the 192 
population was restricted to screened girls/women, to limit the impact of changes in screening 193 
recommendations/participation since the introduction of HPV vaccination. Finally, because our aim was to examine the 194 
population-level impact of HPV vaccination programs, we excluded studies if HPV vaccination was administered as part of 195 
a randomized trial, and/or if there were no data available for the pre-vaccination period.  196 
 197 
To update our first systematic review (Jan 1, 2007 to Feb 28, 2014), we searched Medline and Embase between Feb 1, 2014 198 
and October 11, 2018, with the same combination of Medical Subject heading (MeSH) terms, title, or abstract words 199 
(“papillomavirus vaccine”, “papillomavirus vaccination”, “HPV vaccine”, or “HPV vaccination”) and (“program 200 
evaluation”, “population surveillance”, “sentinel surveillance”, “incidence”, or prevalence”), and (“papillomavirus 201 
infection”, “condylomata acuminata”, “anogenital warts”, “cervical intraepithelial neoplasia”, “cervical dysplasia”, “uterine 202 
cervical neoplasm”, or “HPV related diseases”) (Appendix Table S2). The identification of eligible articles was performed 203 
independently by EB or NP and MD on title and abstract first, and then on the full-text. Disagreement between reviewers 204 
was solved by discussion between those authors.  Finally, we searched the reference lists of selected articles. If more than 205 
one publication from the same data sources and/or research team was available, we kept the publication presenting the most 206 
recent or exhaustive data. 207 
 208 
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Data extraction and quality assessment 209 
Our primary outcome was the relative risk (RR) comparing the frequency (prevalence or incidence) of HPV-related 210 
endpoints between the pre- and post-vaccination periods. For HPV infection, we focussed on three subgroups of HPV types: 211 
1) HPV-16/18, 2) HPV-31/33/45, 3) all high-risk types except HPV16/18. MD, EB, and NP extracted the study 212 
characteristics and outcomes using a standardised form. MD, EB, NP and MB assessed the methodological quality of all 213 
studies, independently from the authors of the original studies, using the criteria developed for our first systematic review 214 
(Appendix Tables S5-S7). Potential biases and confounding were assessed by examining the procedures to select or identify 215 
participants, endpoint definitions, algorithms used to identify cases, and potential confounders (specific to each HPV-related 216 
endpoint) considered in the analysis. Then, MD contacted all corresponding authors of eligible studies to request a re-217 
analysis of their data using the same data stratifications (e.g., age groups, HPV type grouping) to allow comparison between 218 
studies and pooling and all authors were able to provide these data. In collaboration with authors from the different 219 
countries, MD, EB, and NP also collected detailed information about the characteristics of each country/region HPV 220 
vaccination programs (routine program and catch-up campaigns), vaccination coverage, and cervical cancer screening 221 
recommendations/participation (Appendix Tables S3-S4). Finally, all authors of eligible studies validated that the 222 
information and data from their study, which were included in the manuscript, were accurate. 223 
 224 
Data analysis 225 
For all endpoints, we stratified all analyses by sex, age and years since the introduction of HPV vaccination. A priori, we 226 
chose to present the RRs stratified into two time categories to reflect the post-vaccination follow-up period used in our first 227 
meta-analysis (1-4 years), and the additional years available for the current update (5-8 years for HPV infections and 228 
anogenital warts / 5-9 years for CIN2+). In addition, we stratified analyses for anogenital warts by the type of vaccine (since 229 
only the quadrivalent vaccine includes HPV-6/11, which are associated with 85-95% of anogenital warts7). We used 230 
prevalence or incidence rate ratios as the measure of effect for all HPV-related endpoints (according to the data available 231 
from each study). For HPV infections, most studies directly presented crude and/or adjusted relative risk (RR) with 95% 232 
confidence intervals (CI). We preferably included RR adjusted for indicators of sexual activity and/or socio-economic status 233 
in the meta-analysis, but we used crude RR if adjusted estimates were not available. For anogenital warts and CIN2+, 234 
studies presented the annual frequency (prevalence or incidence) of the endpoint over time for the pre- and post-vaccination 235 
periods. Hence, for these endpoints, we estimated pre-vaccination frequency by aggregating the data for up to 3 years before 236 
vaccination and calculated crude RR by dividing each post-vaccination year by the pre-vaccination estimate (Appendix 237 
Table S8). We used random-effects models on a log scale to obtain pooled estimates of the effect of HPV vaccination for 238 
each HPV-related endpoint,8, 9 using Review Manager version 5.3.5. We used I² and χ² statistics to assess heterogeneity 239 
across studies, and the p value associated with the χ² statistic represents the statistical significance of heterogeneity.10 240 
 241 
The number of studies available for each HPV-related endpoint was too small to perform multivariate meta-regression.10 242 
Therefore, we performed subgroup analyses to identify the main sources of heterogeneity between studies. Firstly, we 243 
examined the impact of vaccination coverage and number of vaccinated cohorts, given that vaccination of a single or 244 
multiple cohorts is a key policy question. Because HPV endpoints were estimated from different types of studies, the 245 
available information about vaccination coverage and number of cohorts vaccinated varied across type of endpoints. For 246 
HPV infections, the vaccination status was directly available for all study participants (except for Dillner et al.11). Hence, we 247 
used the age-specific proportion of individuals vaccinated with at least one dose in each study and dichotomized the studies’ 248 
vaccination coverage into < 50% and ≥ 50%. For anogenital warts, most studies were based on population or insurance 249 
registries of a country/region. Hence, we used the overall proportion of people vaccinated in the country/region and 250 
dichotomized the studies’ country/region into: 1) Medium/high proportion of people vaccinated: country/region vaccinating 251 
multiple cohorts of girls with a vaccination coverage ≥ 50% for at least 2 doses among the routine cohort, and 2) Low 252 
proportion of people vaccinated: country/region vaccinating a single cohort of girls and/or having a coverage for at least 2 253 
doses < 50% among the routine cohort. For CIN2+, studies were based on screened girls/women from screening registries. 254 
However, because the vaccination coverage was not available for screened girls/women for all studies, we used the overall 255 
country/regional level data and used the same categories as for anogenital warts (see Appendix Table S3). Secondly, we 256 
examined the impact of the vaccine used (bivalent, quadrivalent) and the data source (population-based, health 257 
provider/insurance-based, clinic-based) for all endpoints. Thirdly, we examined relevant endpoint-specific sources of 258 
heterogeneity. Because studies on HPV infection reported either adjusted or crude RR, we examined the impact of RR 259 
adjustment (yes, no). Finally, because CIN2+ detection can be influenced by screening recommendations/participation, we 260 
examined the potential impact of using HPV testing (yes, no) during the study period and the potential impact of changes 261 
that occurred during the study period: introduction of HPV testing (yes, no), older age at screening start (yes, no), and 262 
changes in the screening interval during the study period (yes, no). 263 
 264 
 265 
 266 
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Role of the funding source 267 
The funders had no role in the study design, data collection, analysis and interpretation, or writing of the report. MB had full 268 
access to all the data in the study and had final responsibility for the decision to submit for publication. 269 
  270 
RESULTS 271 
We identified 1702 potentially eligible new articles (published between Feb 1, 2014 and Oct 11, 2018), of which 47 eligible 272 
articles were added to our first review for an overall total of 65 articles included in this systematic review (23 articles for 273 
HPV infection,11-33 29 articles for anogenital warts,34-62 and 13 articles for CIN2+63-75) (Figure 1). These studies were 274 
conducted in fourteen high-income countries and cumulated data from more than 60 million individuals over 8 years (2007-275 
2015) (Table 1). The vaccination programs, vaccination coverage (Appendix Table S3), and cervical screening 276 
recommendations/participation (Appendix Table S4) varied substantially between countries. As of 2015 (year of the most 277 
recent available data), 12/14 countries included in the review were vaccinating females-only with 3 doses of the bivalent or 278 
quadrivalent vaccine (Appendix Table S3). The only exceptions were Australia and the USA. Australia switched to a 279 
gender-neutral program in 2013 (i.e., year 6 after the implementation of HPV vaccination) and the USA recommended 280 
gender-neutral vaccination in 2011 (2-dose vaccination coverage among males remained below 20% until 2013, year 7 after 281 
the implementation of HPV vaccination). The age of girls/women targeted for vaccination also varied between countries 282 
(Appendix Table S3). The age of routine vaccination varied slightly between countries, from 10 to 13 years old. Most 283 
countries with multi-cohort vaccination targeted girls up to 18 years of age through routine and catch-up programs. 284 
However, Australia, the USA, and Denmark targeted women up to 26 years of age (with decreasing coverage as age 285 
increased). All studies were of sufficiently high methodological quality to be included in the meta-analysis (Appendix 286 
Tables S5-S7). 287 
 288 
HPV Infection 289 
In the first four years following the introduction of HPV vaccination, HPV-16/18 prevalence decreased significantly among 290 
girls aged 13-19 years and women aged 20-24 years compared to the pre-vaccination period (Figure 2, Appendix Figure 291 
S1). After 5-8 years of vaccination, HPV-16/18 prevalence decreased significantly by 83% (RR 0·17 [95% CI 0·11–0·25]) 292 
and 66% (RR 0·34 [95% CI 0·23–0·49]) among girls aged 13-19 years and women aged 20-24 years, respectively, 293 
compared to the pre-vaccination period. No significant changes in HPV-16/18 prevalence were observed among women 294 
aged 25-29 years (mostly unvaccinated) during the first four years of vaccination whereas a significant decrease was 295 
observed during the 5-8 year follow-up period (RR 0·63 [95% CI 0·41-0·97].  296 
 297 
For HPV-31/33/45 (cross-protective types), there were substantial but non-significant decreases in prevalence during the 298 
first 4 years of vaccination among girls aged 13-19 years. However, after 5-8 years of vaccination, HPV-31/33/45 299 
prevalence decreased significantly by 54% (RR 0·46 [95% CI 0·33–0·66]) among girls aged 13-19 years and non-300 
significantly by 28% (RR 0·72 [95% CI 0·47–1·10]) among women aged 20-24 years. No significant changes in HPV-301 
31/33/45 prevalence were observed among women aged 25-29 years during the 0-4 and 5-8 year follow-up periods. Finally, 302 
although non-significant, slight increases in the prevalence of high-risk types not included in the vaccine were observed for 303 
all age groups.  304 
 305 
In subgroup analyses, studies where participants had a high vaccination coverage (≥ 50%) generally had greater decreases in 306 
HPV-16/18 and HPV-31/33/45 prevalence compared to studies with a low vaccination coverage (<50%), but the differences 307 
were not always statistically significant (Appendix Table S9). Studies using clinic-based data also showed greater decreases 308 
in HPV-16/18 prevalence compared to studies using population-based data. Studies with a high vaccination coverage and/or 309 
using clinic-based data showed greater increases in high-risk HPV types other than 16/18 among girls aged 13-19 years and 310 
during the first 4 years of vaccination. However, these differences were not maintained with a longer post-vaccination 311 
follow-up and were not consistent across the different age groups. 312 
 313 
Only two studies were available for genital HPV infections among males (Appendix Figure S1 D,E).13, 31 Non-significant 314 
decreases in HPV-16/18 (RR 0·35 [95% CI 0·09–1·40]) and HPV 31/33/45 (RR 0·31 [95% CI 0·06–1·58]) prevalence were 315 
observed among boys aged 16-19 years during the first 4 years of girls-only vaccination. The decreases were very similar 316 
after 5-8 years of vaccination in the study by Chow et al.13 No significant changes were observed among men aged 20-24 317 
years. 318 
 319 
Anogenital Wart Diagnoses     320 
In the first four years following the implementation of quadrivalent HPV vaccination, anogenital wart diagnoses decreased 321 
significantly among girls/women aged 15-19, 20-24 years, and 25-29 years. In addition, non-significant but substantial 322 
decreases were observed among unvaccinated boys aged 15-19 years (Figure 3, Appendix Figure S2). After 5-8 years of 323 
HPV vaccination, declines in anogenital wart diagnoses were significant for girls/women aged 15-29 years and for 324 
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boys/young men (Figure 3). Anogenital wart diagnoses decreased significantly by 67% (RR 0·33 [95% CI 0·24–0·46]) and 325 
31% (RR 0·69 [95% CI 0·53–0·89]) among girls aged 15-19 years and women aged 25-29 years, respectively, and by 48% 326 
(RR 0·52 [95% CI 0·37–0·75]) and 32% (RR 0·68 [95% CI 0·47–0·98]) among boys aged 15-19 years and young men aged 327 
20-24 years, respectively. Three studies examined changes in anogenital wart diagnoses following the implementation of 328 
bivalent vaccination and results suggest a slight decrease among girls/women aged 15-19 and 20-24 years, and boys aged 329 
15-19 years (Appendix, Figure S2 A,B, E, F). 330 
 331 
In subgroups analyses, studies conducted in countries with multi-cohort vaccination and a population-level vaccination 332 
coverage ≥ 50% consistently showed greater decreases in anogenital wart diagnoses among females and males and among 333 
different age groups (Appendix, Table S10). Studies using clinic-based data also showed greater decreases of anogenital 334 
wart diagnoses compared to studies using population-based data.  335 
 336 
Figure 4 shows changes over time in anogenital wart diagnoses among females and males, taking into consideration the 337 
main sources of heterogeneity. This figure clearly illustrates the rapid and significant decline in anogenital wart diagnoses 338 
over time among girls/women and boys/men aged 15-19, 20-24 and 25-29 years, in countries vaccinating multiple cohorts 339 
of girls/women with high routine vaccination coverage. On the other hand, the decline was slower in countries vaccinating a 340 
single cohort of girls or having low routine vaccination coverage, with significant decreases observed among girls/women 341 
aged 15-19 and 20-24 years, only in the third years of vaccination. In addition, in these countries, increases in anogenital 342 
wart diagnoses were observed among the oldest cohorts of men (Figure 4B). A sensitivity analysis restricted to countries 343 
with high vaccination coverage (≥50%), showed that multi-cohort vaccination provided substantial additional reductions in 344 
anogenital wart diagnoses than single-cohort vaccination (Appendix Figure S4). 345 
 346 
CIN2+ 347 
In the first four years following the introduction of HPV vaccination, significant CIN2+ decreases were only observed 348 
among screened girls aged 15-19 years (Figure 5, Appendix Figure S3). After 5-9 years of HPV vaccination, CIN2+ 349 
decreased significantly by 51% (RR 0·49 [95% CI 0·42–0·58]) and 31% (RR 0·69 [95% CI 0·57–0·84]) among screened 350 
girls aged 15-19 years and women aged 20-24 years, respectively. However, during the same follow-up period, CIN2+ 351 
increased significantly by 19% RR 1·19 [95% CI 1·06–1·32]) and 23% (RR 1·23 [95% CI 1·13–1·34]) among screened and 352 
mostly unvaccinated women aged 25-29 and 30-39 years, respectively.  353 
 354 
In subgroup analyses, countries with multi-cohort vaccination and high routine vaccination coverage produced greater 355 
decreases in CIN2+ among girls/women aged 15-24 years old than the country with single-cohort vaccination and/or low 356 
routine vaccination coverage (Appendix, Table S11). The only study from a country using the bivalent vaccine also showed 357 
greater decreases in CIN2+ among women aged 20-24 years, compared to studies from countries using the quadrivalent 358 
vaccine (although the country using the bivalent vaccine also had very high vaccination coverage). Subgroup analyses also 359 
showed that increases in CIN2+ among women aged 25-29 years during post-vaccination years were significantly greater in 360 
the country with single-cohort vaccination and/or low routine vaccination coverage. None of the variables related to changes 361 
in screening recommendations/participation since the introduction of HPV vaccination were clearly associated with changes 362 
in CIN2+.  363 
 364 
Figure 6 shows changes in CIN2+ among screened girls/women, taking into consideration the main sources of heterogeneity 365 
(excluding the results from the only country with single-cohort vaccination). Significant declines in CIN2+ were observed 366 
among girls aged 15-19 years and women aged 20-24 years after one and three years of vaccination, respectively. On the 367 
other hand, significant increases in CIN2+ were observed among mostly unvaccinated women aged 25-29 and 30-39 years. 368 
 369 
DISCUSSION 370 
 371 
This systematic review and meta-analysis, including data from 14 high-income countries, shows a significant and 372 
substantial impact of HPV vaccination on three HPV-related endpoints in the first 9 years after the start of HPV vaccination. 373 
Over this time period, HPV-16/18 infections, anogenital wart diagnoses and CIN2+ decreased significantly by about 80%, 374 
70%, and 50%, respectively, among girls aged <20 years, and by 65%, 55%, and 30% among women aged 20-24 years. 375 
There was also evidence of vaccine cross-protection and herd effects from girls-only vaccination programs. HPV-31/33/45 376 
decreased significantly by 50% among girls aged <20 years, and anogenital wart diagnoses decreased significantly by 30-377 
50% among boys/men aged 15-24 years and by 30% among women aged 25-29 years. Finally, our meta-analysis illustrates 378 
the greater and faster direct impact and herd effects of HPV vaccination in countries with both multi-cohort vaccination and 379 
high routine vaccination coverage compared to countries with single-cohort vaccination and/or low routine vaccination 380 
coverage. For example, after 5-8 years of HPV vaccination, anogenital wart diagnoses declined by 88% and 86% among 381 
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girls and boys aged <20 years, respectively, in countries with multi-cohort vaccination and high routine vaccination 382 
coverage compared to 44% and 1% in countries with single-cohort vaccination and/or low routine vaccination coverage.   383 
 384 
Our study is the first to show the real-world additional benefit of multi-cohort HPV vaccination and high routine 385 
vaccination coverage. After 5-8 years of vaccination, reductions in anogenital wart diagnoses and CIN2+ among girls aged 386 
15-19 years were 44 and >100 percentage points greater, respectively, compared to countries with single-cohort vaccination 387 
and/or low routine vaccination coverage. Fast and substantial herd effects were also observed in countries with multi-cohort 388 
vaccination and high routine vaccination coverage. After 5-8 years of girls-only vaccination, reductions in anogenital wart 389 
diagnoses were 85 percentage points greater among boys aged 15-19 years old compared to single-cohort vaccination and/or 390 
low routine vaccination coverage. These results were similar when restricting the analysis to countries with high routine 391 
vaccination coverage. Our results are also in line with a recent mathematical modeling study, which estimated that five 392 
years after the introduction of HPV vaccination in Australia, half of the observed declines in anogenital wart diagnoses were 393 
attributable to multi-cohort vaccination (catch-up of 14-26-year-old females) (Appendix Table S3).76 In terms of policy 394 
implications, these results reinforce the recently revised position of the WHO, recommending HPV vaccination of multiple 395 
age cohorts of girls (9-14 years old) when introducing the vaccine in a country, rather than vaccination of a single cohort,5 396 
to obtain faster and greater population-level impact. However, the optimal number of age cohorts to vaccinate remains an 397 
open question and may be country specific. Increasing the number of cohorts will increase the population-level impact, but 398 
with diminishing returns on investment for each additional older cohort included. Number needed to vaccinate (NNV) and 399 
cost-effectiveness analyses in high income countries suggest that vaccinating multiple cohorts up to 18 years old is highly 400 
efficient and cost-effective.76, 77 However, efficiency (effectiveness per vaccine dose) decreases after 18 years of age, as a 401 
high proportion of individuals will already have been infected by HPV vaccine types at the time of vaccination, and 3 doses 402 
are required (vs the recent recommendations of 2 doses for persons vaccinated before age 15 years 78, 79). Hence, 403 
decisions/recommendations about the number of age cohorts to be vaccinated is a trade-off between goals of maximising 404 
population-level impact (e.g., to reach HPV or cervical cancer elimination goals within a specific time frame) or optimising 405 
vaccination efficiency and return on investment (e.g., NNV and incremental cost-effectiveness ratios).  In addition, several 406 
key factors such as competing priorities, and vaccine affordability and availability can also influence decisions about multi-407 
cohort vaccination. Finally, our results also have implications for the interpretation of surveillance studies. The number of 408 
cohorts vaccinated should be considered in addition to the vaccination coverage when comparing surveillance data between 409 
countries, as the main driver of HPV vaccination impact is the total percent of the population vaccinated.  410 
 411 
Importantly, we also present the first pooled estimates of the population-level impact of HPV vaccination on CIN2+, which 412 
is the most proximal outcome to cervical cancer and is recognised as a valid proxy for vaccine efficacy against cervical 413 
cancer by regulatory agencies worldwide.80-83 The results are the strongest yet that HPV vaccination is working to prevent 414 
cervical cancer in real-world settings, as both the cause (high-risk HPV infection) and proximal disease endpoint are 415 
significantly declining. These results can also inform potential changes to cervical screening programs. Substantial declines 416 
in high-risk HPV types and CIN2+ may allow for older age of start of screening and longer screening intervals. However, 417 
when examining changes in screening in the era of vaccination, careful attention will have to be focussed on unvaccinated 418 
cohorts of women. The decreasing HPV prevalence observed in several settings also support arguments in favour of 419 
switching from cytology alone to primary HPV testing followed by cytology triage to benefit from the higher sensitivity of 420 
HPV testing to detect pre-cancer lesions and higher specificity of cytology, without substantially increasing false positive 421 
results.84.  However, CIN2+ surveillance data among screened girls/women should be interpreted with caution. First, the 422 
greatest and fastest reductions in CIN2+ are among an age group (15-19 years old) not always recommended for screening, 423 
and in which the proportion of those screened has been declining both before and since the introduction of HPV vaccination 424 
due to efforts in the countries to improve adherence to guidelines (Appendix Table S4). Therefore, although we restricted 425 
our analysis to screened girls/women, changes towards a lower risk profile among those that are still screened in this age 426 
group could partly contribute to decreases in CIN2+. However, to our knowledge, there is currently no data supporting 427 
changes in the risk profiles of screened women in the younger age groups since the introduction of HPV vaccination.  428 
Second, several studies have shown that participation in cervical screening and vaccination uptake are associated with the 429 
same socio-demographic factors (e.g., ethnicity, socioeconomic level, education),85-90 and therefore vaccination coverage 430 
among screened girls/women may be different 91, and potentially higher, than country/regional level vaccination coverage in 431 
some settings. Thirdly, major recent changes in screening recommendations, clinical management recommendations, and/or 432 
participation have been documented in several countries in the years surrounding the introduction of HPV vaccination. For 433 
example, the use of HPV testing (mainly as triage of low-grade lesions, which led to increased colposcopy referrals) and/or 434 
longer routine screening intervals, which are likely to increase the CIN2+ detection rate,65 have been reported in the USA, 435 
Denmark, and Norway (Appendix, Table S4). As done in the Scottish study,75 future surveillance studies should include, if 436 
possible, the vaccination coverage of screened girls/women to more accurately quantify the impact of HPV vaccination on 437 
CIN2+. 438 
 439 
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By examining three main HPV-related endpoints concurrently, we can better understand trends in post-vaccination 440 
surveillance data, and draw stronger conclusions about the population-level effectiveness and herd effects of HPV 441 
vaccination. Of particular interest are the results suggesting increases in HPV-related endpoints among population 442 
subgroups not targeted by vaccination: 1) high-risk non-vaccine HPV types, 2) anogenital wart diagnoses among men aged 443 
25-39 years (particularly in countries with single-cohort vaccination and/or low vaccination coverage of girls), and 3) 444 
CIN2+ among screened women aged 25-39 years. Data from several countries suggest that increases in anogenital warts 445 
diagnoses 34, 38, 43, 47, 50, 54 and CIN2+ 63, 92 began before the introduction of HPV vaccination. Together, these results suggest 446 
that the population-level impact of HPV vaccination could currently be measured within an underlying context of increasing 447 
HPV-related endpoints in some countries. Although the reasons for these trends are likely multi-factorial and endpoint-448 
specific, several hypotheses can be made. First, increases in the three HPV-related endpoints could reflect increases in 449 
sexual activity. Several data sources indicate that, over the past 10 to 20 years, the number of sexual partners has increased 450 
and/or the age at sexual initiation has decreased in several high-income countries.24, 93-101 Second, endpoint-specific 451 
hypotheses could also explain observed increases. Increases in high-risk non vaccine HPV types could partly be explained 452 
by HPV-16/18 unmasking (i.e., apparent increased detection of non-vaccine HPV types in a post-vaccination population 453 
with fewer HPV-16/18 infections, which could have masked detection of other HPV types prior to vaccination) 102 or less 454 
likely by type-replacement (i.e., increased prevalence of non-vaccine HPV types occupying the ecological niche created by 455 
preventing HPV-16/18 infections).103 Increases in anogenital wart diagnoses could be partly explained by increased 456 
knowledge, awareness, and health seeking behaviour of the general population about anogenital warts and/or better 457 
diagnosis/reporting by health professionals. Finally, as previously discussed, increases in CIN2+ could be attributable to 458 
changes in screening recommendations, tests, and/or participation documented in several countries. More research is needed 459 
to better understand the factors influencing the increases in trends in non HPV vaccine types and HPV-related diseases in 460 
older females and males. If they are due to changes in sexual behaviour or increased health seeking behaviour/diagnoses, 461 
population-level effectiveness may be underestimated when comparing the annual frequency of HPV-endpoints between 462 
pre- and post-vaccination periods.  463 
 464 
In addition to the epidemiological and public health insights discussed above, our study has important additional strengths. 465 
All corresponding authors were contacted in order to have standardized age groups and HPV-endpoints permitting pooling 466 
of results. Furthermore, the large pooled sample size of person-time at risk and 8-year follow-up since the introduction of 467 
HPV vaccination gave sufficient statistical power to demonstrate declines in all three HPV-related endpoints among 468 
girls/women targeted for vaccination in both high and low coverage settings, and cross-protection and herd effects in 469 
countries with high vaccination coverage and multi-cohort vaccination. Our results should however be interpreted 470 
considering the following three limitations. First, because this meta-analysis is based on ecological studies, causality 471 
between HPV vaccination and the observed changes in HPV-related endpoints cannot be concluded definitively. However, 472 
the: 1) larger and faster decreases in HPV-related endpoints among cohorts targeted for vaccination and in countries with 473 
multi-cohort vaccination and high routine vaccination coverage, 2) larger decreases in HPV-related endpoints with longer 474 
follow-up since the introduction of HPV vaccination (as the number of cohorts vaccinated increases), and 3) consistency 475 
between the results from the different studies and between the three HPV-related endpoints, strongly suggest that the 476 
decreases can be largely attributed to HPV vaccination. Second, the number of post-vaccination studies is not yet sufficient 477 
to perform multivariate meta-regression in order to simultaneously consider the influence of different program 478 
characteristics or study designs. In addition, the number of studies within categories is sometimes limited. For example, 479 
greater decreases in CIN2+ were observed in the only study using the bivalent vaccine (from Scotland) compared to the 480 
studies using the quadrivalent vaccine. However, it was not possible to tease out the effect of the vaccine type given that 481 
Scotland has very high HPV vaccination coverage, had catch-up vaccination, and had no major change in screening 482 
recommendation/behaviour since the introduction of HPV vaccination. Third, our results should be extrapolated to low- and 483 
middle-income countries with caution, as all studies identified in the systemic review are from high-income countries. The 484 
population-level impact of HPV vaccination, including the impact of multi-cohort vaccination strategies, may be different in 485 
countries that have substantially different sexual behaviour (e.g., age at start of sexual activity, age-difference between 486 
partners, concurrency in partnerships, percent of men that are clients of female sex workers), HPV epidemiology, and/or 487 
prevalence of HPV infection/disease cofactors (e.g., HIV).  488 
 489 
In conclusion, the results of this meta-analysis, including data from >60 million individuals from 14 high-income countries, 490 
show compelling evidence of the substantial impact of three-dose girls-only HPV vaccination programs with the 491 
quadrivalent or bivalent vaccines on infections by HPV-16/18 and 31/33/45 as a group, anogenital wart diagnoses and 492 
CIN2+ among women, and herd effects among boys and older women. In addition, programs with multi-cohort vaccination 493 
and high vaccination coverage lead to a greater and faster direct impact and herd effects. These results should be considered 494 
within the rapidly changing landscape of HPV vaccination, with several countries recently switching to 2-dose schedules, 495 
gender-neutral vaccination, and/or the nonavalent vaccine, and research examining 1-dose HPV vaccination, 2-doses in 496 
older populations, and cervical cancer elimination strategies. Although challenging, it will be crucial to continue monitoring 497 
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the population-level impact of HPV vaccination to examine the full impact of these changes in vaccination strategies and to 498 
quantify the impact of vaccination in low- and middle-income countries.  499 
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Table 1. Characteristics of the studies included in the systematic review and meta-analysis 
Author 
(Country) 
Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect measure 
in publication 
Effect 
measure 
recalculated ß  
HPV infection 
         
Chow 2015a 
Chow 2017 
(Australia) 12, 13 
Quadrivalent Clinic-based: STI 
clinics 
Females and males 15-
25 yrs attending the 
Melbourne Sexual 
Health Centre diagnosed 
with chlamydia 
Females and males 
15-24 yrsΩ 
Prevaccine:2005-2007 
Postvaccine:2008-2014 
 
Females 
N prevaccine:128 
N postvaccine:260 
Males 
N prevaccine:115 
N postvaccine:411 
HPV+ PapType HR HPV 
genotyping kit (Genera 
Biosystem) Females: 
cervical & vaginal swabs 
Males: urine and urethal 
swabs 
Crude HPV 
prevalence  
over time 
RR of HPV 
prevalence 
(crude) 
Cummings 2012 
(U.S.)14 
Quadrivalent Clinic-based: 
Primary care clinics 
Females 14-17 yrs 
attending 1 of 3 urban 
primary care clinics in 
Indianapolis 
Females  
14-17 yrs 
Prevaccine:1999-2005 
Postvaccine:2010 
N prevaccine:150 
N postvaccine:75 
HPV+ Roche Linear Array 
(Roche, 37 types) 
OR of HPV 
prevalence 
(crude) 
RR of HPV 
prevalence 
(crude) 
Dillner 2018 11 Quadrivalent Clinic-based: 
Nationwide cervical 
screening program 
of Denmark, 
Sweden, Norway 
Females 18-50 attending 
routine cervical cancer  
Females  
18-29 yrs  
from Denmark 
and Sweden** 
Prevaccine: 2006-2008 
Postvaccine: 2012-2013 
Denmark/ Sweden 
N prevaccine:  
1,188/1,112 
N postvaccine: 
1,163/1,164 
 
HPV+ Luminex system 
(Bio-Rad, 35 types) 
Difference of 
HPV prevalence 
(crude) 
RR of HPV 
prevalence 
(crude) 
Dunne 2015 
(USA)15 
 
Quadrivalent Clinic-based: 
Kaiser Permanente 
NorthWest 
 
Females 20-29 yrs 
attending routine 
cervical cancer screening 
(cytology) 
Females 
 20-29 yrs 
Prevaccine:2007 
Postvaccine:2012-2013 
N prevaccine:4,138 
N postvaccine:4,171 
HPV+ Roche Linear Array 
& HPV-52 quantitative 
PCR 
RR of HPV 
prevalence 
(crude) 
RR of HPV 
prevalence 
(crude) 
Grün 2016 
(Sweden)16 
Quadrivalent Clinic-based: Youth 
clinic in Stockholm 
Females and males (oral 
infections for males) 15-
23 yrs attending a 
Stockholm youth clinic 
Females   
15-23 yrsΩ 
Prevaccine: 2008-2011 
Postvaccine: 2013-2015  
N prevaccine: 544 γ 
N postvaccine: 332 
HPV+ Luminex-based 
genotyping assay (27 
types) 
Crude HPV 
prevalence over 
time 
RR of HPV 
prevalence 
(crude) 
Kavanagh 2014/ 
Cameron 
2016/Kavanagh 
2017(Scotland)17-19 
Bivalent Clinic-based: 
Scottish Cervical 
screening Call & 
Recall System  
Females 20-21 yrs 
participating in cervical 
cancer screening in 
Scotland 
 
Females  
20-21 yrs 
Prevaccine:2009-2010 
Postvaccine1:2011-2012 
Postvaccine2:2013-2015 
N prevaccine:2,705 
N postvaccine1:1,994 
N postvaccine2:3,702 
 
HPV+ Multimetrix HPV 
assay (18 types) 
Crude HPV 
prevalence over 
time  
RR of HPV 
prevalence 
(crude) 
Kahn 2012/ 
Kahn 2016 
(USA)20, 21 
Quadrivalent Clinic-based: 
Hospital and health 
department 
Females 13-26 yrs 
attending 1 hospital-
based teen clinic and 2 
health department sites 
in Cincinnati 
Females  
13-26 yrs,  
Had had sexual 
contact 
 
Prevaccine:2006-2007 
Postvaccine1:2009-2010 
Postvaccine2:2013-2014 
N prevaccine:355 
N postvaccine1:408 
N postvaccine2:400 
HPV+ Roche Linear Array 
(Roche, 37 types) 
HPV prevalence 
difference 
(adjusted)  
RR of HPV 
prevalence 
(adjusted) 
Machalek 2018 Ŧ 
(Australia) 22 
Quadrivalent Clinic-based: 
Family planning 
clinics 
Females 18-35 yrs 
attending family 
planning clinics in 
Victoria and New South 
Wales 
Females 
25-29 yrs  
Prevaccine:2005-2007 
Postvaccine:2015 
N prevaccine:102 
N postvaccine:114 
2005-2007: HPV+ Roche 
Linear Array (13 types), 
2015: Cobas HPV test 
(Roche Diagnosis) and 
Roche Linear Array 
genotyping test (37 types) 
RR of HPV 
prevalence 
(adjusted) 
RR of HPV 
prevalence 
(adjusted) 
Markowitz 2013/ 
Markowitz 2016 / 
Oliver 2017 
(USA)23-25 
Quadrivalent Population-based: 
NHANES 
participants  
Nationally representative 
sample of USA females 
aged 14-59 yrs 
Females  
14-29 yrs 
 
Prevaccine:2003-2006 
Postvaccine1:2007-2010 
Postvaccine2:2011-2014 
N prevaccine:2,198 
N postvaccine1:1,599 
N postvaccine2:1,634 
HPV+ Roche Linear Array 
(Roche, 37 types) 
RR of HPV 
prevalence 
(adjusted) 
RR of HPV 
prevalence 
(adjusted) 
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(Country) 
Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect measure 
in publication 
Effect 
measure 
recalculated ß  
Mesher 2013/ 
Mesher 2016/ 
Mesher 2018 
(England)26-28 
Bivalent Clinic-based: 
Community sexual 
health clinics, GP 
Females 16-24 yrs 
undergoing chlamydia 
screening in community 
sexual health / GP 
/Youth clinics in 7 
regions around England 
Females  
16-24 yrs 
Prevaccine:2008 
Postvaccine1:2010-2012 
Postvaccine2:2013-2016 
N prevaccine:2,354 
N postvaccine1:7,924 
N postvaccine2:7,535 
2008: Hybrid Capture 2 
and Roche Linear Array 
≥2010: HPV+ In-house 
multiplex PCR and Luminex-
based genotyping (18 types)‖  
OR of HPV 
prevalence 
(adjusted) 
RR of HPV 
prevalence 
(adjusted) 
Purriños-Hermida 
2018 (Spain) 29 
Bivalent Clinic-based: 
Primary care center, 
gynecology 
department, family 
counseling center 
Females 18-26 yrs 
attending  health areas of 
the Galician Public 
Health Services 
Females 
18-26 yrs 
Prevaccine:2008-2010 
Postvaccine:2014-2017 
N prevaccine:523 
N postvaccine:745 
HPV+ Cobas 4800 HPV 
test with Linear Array 
HPV genotyping (Roche 
Diagnostic) (12 types) 
RR of HPV 
prevalence 
(crude and 
adjusted) 
RR of HPV 
prevalence 
(adjusted) 
Söderlund-Strand 
2014 
(Sweden)30 
 
Quadrivalent Clinic-based: 
Chlamydia 
screening  
Females all ages 
attending to Chlamydia 
screening 
Females  
15-29 yrs 
Prevaccine:2008 
Postvaccine:2012-2013 
N prevaccine:15,767 
N postvaccine:5216 
HPV + In-house multiplex 
PCR with genotyping by 
MALDI-TOF mass 
spectrometry (16 types) 
Crude HPV 
prevalence over 
time 
RR of HPV 
prevalence 
(crude) 
Sonnenberg 2013 
(England, Scotland, 
Wales) 31 
Bivalent Population-based: 
Natsal participants 
Nationally representative 
sample of males and 
females aged 16-44 yrs 
Natsal-2, 16-74 yrs 
Natsal-3 in Britain 
 
Females and 
males 
18-29 yrs 
Prevaccine:1999-2001 
Postvaccine:2010-2012 
Females 
N prevaccine:684 
N postvaccine:1,426 
Males 
N prevaccine:462 
N postvaccine:1061 
HPV+ In-house Luminex-
based genotyping assay (18 
types)‖  in urine samples 
OR of HPV 
prevalence 
(age-adjusted) 
RR of HPV 
prevalence 
(age-adjusted) 
Tabrizi 2012/2014 
(Australia)32, 33 
Quadrivalent Clinic-based: 
Family planning 
clinics 
Females 18-24 yrs 
attending 1 of 6 family 
planning clinics in 
Sydney, Melbourne, 
Perth 
Females  
18-24 yrs 
 
Prevaccine:2005-2007 
Postvaccine1:2010-2011 
Postvaccine2:2010-2012 
N prevaccine:202 
N postvaccine1:404 
N postvaccine2:1,058 
HPV+ Roche Linear Array 
(13 types),  
 
RR of HPV 
prevalence 
(adjusted) 
RR of HPV 
prevalence 
(adjusted) 
Anogenital warts    
Ali 2013/  
Chow 2015b, Ali 
2017, Callander 
2016 (Australia) 
34-37 
Quadrivalent Clinic-based: STI 
clinics  
New clients of 40 sexual 
health centers across 
Australia aged ≥ 12 yrs 
(Australian born) 
Australian born 
females and 
heterosexual 
males  
15-39 yrs 
2004-2015 
Prevaccine: 2005-2007 
Postvaccine:2008-2015 
 
P-yr prevaccine: 
51,010 
P-yr postvaccine: 
134,614 
Clinical diagnosis Annual 
proportion of 
new clients with 
AGW 
RR of AGW 
proportion 
(crude) 
Baandrup 2013/ 
Bollerup 2016 
(Denmark)38, 39 
Quadrivalent Population-based: 
Statistics Denmark, 
National Patient 
Registry 
Entire population of 
Denmark ≥ 12 yrs 
Females and 
males  
15-39 yrs 
2006-2013 
Prevaccine: 2007-2009 
Postvaccine:2010-2013 
 
P-yr prevaccine: 
5,144,888 
P-yr postvaccine: 
6,945,980 
ICD-10 code A63.0 OR 
prescription of 
Podophyllotoxin  
Annual incidence 
rate of diagnosed 
AGW in the 
population 
RR of AGW 
incidence 
(crude) 
Bauer 2012 
(USA)40 
Quadrivalent Health provider 
/insurance-based: 
Clinical encounters 
claims data of a 
health program 
Clients of the California 
Family Planning access 
care & treatment 
(PACT) program aged ≥ 
10 yrs (87% females) 
Females and males 
15-39 yrs  
Program serves 
low-income 
individuals 
 
2007-2010 
Prevaccine: 2007 
Postvaccine:2008-2010 
P-yr prevaccine: 
1,750,980 
P-yr postvaccine: 
5,555,420 
ICD-9 codes 078.10, 078.11 
OR prescription of 
Imiquimod or 
Podophyllotoxin 
Annual 
proportion of 
PACT clients 
diagnosed with 
AGW 
RR of AGW 
proportion 
(crude) 
Cocchio 2017 
(Italy)41 
Quadrivalent Population-based: 
Hospital records of 
all Veneto residents 
(public & private) 
Entire population from 
Veneto, Italy 
Females and males  
15-39 yrs 
2004-2015 
Prevaccine:2006-2008 
Postvaccine:2009-2015 
P-yr prevaccine: 
4,567,864 
P-yr postvaccine: 
9,913,192 
ICD-9 code 078.11 and 1 
ICD-9 surgical code (70-71, 
58, 64, 58.3, 49) 
Annual rate of 
hospitalization 
for AGW in the 
population 
RR of AGW 
hospitalization 
(crude) 
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Author 
(Country) 
Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect measure 
in publication 
Effect 
measure 
recalculated ß  
Dominiak-Felden 
2015 (Belgium)42 
Quadrivalent Health provider 
/insurance-based: 
Medical claims, 
National Union of 
Independent Sick 
Funds (MLOZ) 
Enrollees in MLOZ, one 
of the 3 biggest sick fund 
in Belgium (18% of the 
Belgium population; 2 
million individuals) 
Females and 
males  
15-39 yrs 
 
2006-2013 
Prevaccine:2006-2007 
Postvaccine:2008-2013 
P-yr prevaccine: 
960,777 
P-yr postvaccine: 
3,858,172 
First prescription of 
Imiquimod with a level of 
reimbursement specific for 
AGW onset 
RR of AGW 
incidence (crude) 
RR of AGW 
incidence 
(crude) 
Flagg 2013/Flagg 
2018 
(USA)43, 44 
Quadrivalent Health provider 
/insurance-based: 
Truven Health 
Analytics Market 
Scan Commercial 
Claims and 
Encounters 
Database 
Enrollees in 
approximately 100 
health private insurance 
plans across the U.S. 
aged 10-39 yrs 
Females and 
males 
15-39 yrs,  
Insured 
employees, early 
retirees and their 
dependents 
2003-2014 
Prevaccine: 2004-2006 
Postvaccine:2007-2014 
 
P-yr prevaccine: 
11,864,207 
P-yr postvaccine: 
85,043,491 
 
1) ICD-9 codes 078.11 OR 2) 
ICD-9 code 078.1, 078.10, or 
078.19 and therapeutic 
procedure  diagnosis of benign 
AG neoplasm OR 3) ≥1 
prescription for AGW 
treatment and therapeutic 
procedure r diagnosis of 
benign AG neoplasm 
Annual 
proportion of 
insured 
individuals with 
diagnosed 
AGW 
RR of AGW 
proportion 
(crude) 
Guerra 2016 
(Canada-Ontario)45 
Quadrivalent Population-based: 
Health care 
encounter database 
(covers all Ontario 
residents) 
All Ontario residents 
aged ≥ 15 yrs with a 
valid health card number 
Females and 
males  
15-26 yrs 
2004-2013 
Prevaccine:2005-2007 
Postvaccine:2008-2013 
P-yr prevaccine: 
6,242,786 
P-yr postvaccine: 
13,069,534 
 
First physician office visit 
(12-month wash-out period) 
with one of 10 possible 
combination codes: 099 + 
Z117, 079 + Z117, 629 + 
Z117, Z549, Z758, Females: 
Z733, Z736, or Z769; males 
Z767, Z701 
Annual 
incidence rate 
of diagnosed 
AGW in the 
population 
RR of AGW 
incidence 
(crude) 
Harrison 2014 Ψ 
(Australia)46 
Quadrivalent Clinic-based 
(BEACH program: 
randomly selected 
GP-encounters in 
Australia) 
Patients of 1,000 
randomly selected GP 
across Australia (each 
year) 
Females and 
males  
15-39 yrs 
2002-2015 
Prevaccine:2005-2007 
Postvaccine:2008-2015 
P-yr prevaccine:  
77,258 
P-yr postvaccine: 
190,268   
ICPC 2 code Y76 (males), 
X91 (females) 
Annual 
proportion of 
patients with 
AGW 
management 
RR of AGW 
management 
proportion 
(crude) 
Howell-Jones 2013/ 
Canvin 2017 
(England) 47, 48 
 
Bivalent 
Quadrivalent 
for some girls 
15-16 yrs in 
2014-2015 α 
Population-based: 
Office for National 
Statistics, 
Genitourinary 
medicine (GUM) 
clinics  
Entire population of 
England aged 15-24 yrs; 
 
Females and 
males 
15-24 yrs 
2002-2015 
Prevaccine: 2006-2008 
Postvaccine:2009-2015 
 
P-yr prevaccine: 
20,370,695 
P-yr postvaccine: 
48,041,371 
 
Clinical diagnosis  
 
Annual 
incidence rate 
of diagnosed 
AGW in the 
population 
RR of AGW 
incidence 
(crude) 
Kliewer 2012/ 
Thompson 2016 
(Canada-
Manitoba)49, 50 
 
Quadrivalent Population-based: 
Medical claims and 
hospital discharge 
database of all 
Manitoba residents 
 
Entire population of 
Manitoba 
Females and 
males  
15-39 yrs 
2006-2011 
Prevaccine: 2006-2008 
Postvaccine:2009-2011 
 
P-yr prevaccine: 
1,194,786 
P-yr postvaccine: 
1,245,073 
 
Treatments (1 of 14 tariff 
codes) OR (hospitalization 
for AGW + ICD-9 code 
078.11) OR (078.1, 
078.10, 078.19 and related 
procedure) OR ICD-10 
A630 OR (B07 and related 
procedure) 
Annual 
incidence rate 
of diagnosed 
AGW in the 
population 
RR of AGW 
incidence 
(crude) 
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Author 
(Country) 
Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect measure 
in publication 
Effect 
measure 
recalculated ß  
Leval 2012/ 
Herweijer 2018 
(Sweden)51, 52 
Quadrivalent Population-based: 
Statistics Sweden, 
National Patient 
Register, Prescribed 
Drug Register 
Entire population of 
Sweden aged ≥ 10 yrs 
Females and 
males 
15-39 yrs 
2006-2012 
Prevaccine: 2006 
Postvaccine:2007-2012 
 
P-yr prevaccine: 
2,930,263 
P-yr postvaccine: 
18,089,134 
 
ICD-10 code A63.0 OR  
prescription of Imiquimod 
or Podophyllotoxin  
Annual incidence 
rate of diagnosed 
AGW in the 
population 
 
RR of AGW 
incidence 
(crude) 
Liu 2014 
(Australia)53 
Quadrivalent Population-based: 
Australia-wide 
survey 
All Australian women 
aged 18-39 yrs 
Females  
18-39 yrs 
2001 and 2011 
Prevaccine:2001 
Postvaccine:2011 
P-yr prevaccine: 
4,874 
P-yr postvaccine: 
2,394 
Self-reported AGW 
diagnosis (ever had AGW) 
Proportion of 
women 
reporting AGW 
among all 
respondents 
RR of AGW 
proportion 
(crude) 
Mikolajczyk 2013/ 
Thönes 2017 
(Germany)54, 55 
 
Quadrivalent Health provider 
/insurance-based: 
German Pharmaco-
epidemiological 
Research Database 
Enrollees in 1 large 
health insurance 
company across 
Germany aged 10-79 yrs 
Females and 
males 
15-39 yrs 
2005-2010 
Prevaccine: 2005-2007 
Postvaccine:2008-2010 
 
P-yr prevaccine: 
4,974,000 
P-yr postvaccine: 
5,372,000 
 
ICD-10 code A63.0 Annual 
incidence rate 
of diagnosed 
AGW among 
insured 
individuals 
RR of AGW 
incidence 
(crude) 
Oliphant 2011/2017 
(New Zealand)56, 57 
Quadrivalent Clinic-based: STI 
clinic 
New clients of 4 sexual 
health service in 
Auckland aged ≥ 10 yrs 
Females and 
males  
15-39 yrs 
 
2007-2013 
Prevaccine:2007-2008 
Postvaccine:2009-2013 
P-yr prevaccine:  
9,559 
P-yr postvaccine: 
26,258 
 
Clinical diagnosis Annual 
proportion of 
new clients 
diagnosed with 
AGW 
RR of AGW 
proportion 
(crude) 
Smith 2015/2016 
(Australia)58, 59 
Quadrivalent Population-based: 
National Hospital 
Morbidity Database, 
Australian Bureau of 
Statistics 
Entire population of 
Australia aged 12-69 yrs  
Females and 
males  
12-69 yrs¥ 
2005-2011 
Prevaccine:2005-2007 
Postvaccine:2008-2011 
P-yr prevaccine: 
45,887,699 
P-yr postvaccine: 
65,192,250  
Hospitalization including 
ICD-10 code A63.0 as 
main or contributory 
diagnosis 
Annual rate of 
hospitalization 
with AGW 
diagnosis in the 
population  
RR of AGW 
hospitalization 
(crude) 
Sonnenberg 2017 60 Bivalent Population-based: 
Natsal participants 
Nationally representative 
sample of males and 
females aged 16-44 yrs 
Natsal-2, 16-74 yrs 
Natsal-3 in Britain 
 
Females and 
males 
16-39 yrs 
Prevaccine:1999-2001 
Postvaccine:2010-2012 
N prevaccine:8,204 
N postvaccine:5,849 
Ever having a diagnosis of 
AGW (self-reported) 
Proportion of the 
population who 
reported ever 
having a 
diagnosis of 
AGW  
RR of AGW 
proportion 
(crude) 
Steben 2018 61 Quadrivalent Health provider 
/insurance-based : 
Quebec physician 
claim and public drug 
insurance databases 
Individuals covered by 
the Quebec public drug 
insurance 
Females and 
males 15- ≥30 yrs 
2004-2012 
Prevaccine:2004-2007 
Postvaccine:2009-2012 
P-yr prevaccine: 
13,159,362 
P-yr postvaccine: 
13,241,313 
ICD-9 code 078.1OR 
medical procedure specific 
to condyloma (05314, 
06169) OR dispensation of 
podofilox, imiquimod, or 
fluorouracil 
Annual incidence 
rate of diagnosed 
AGW among 
insured 
individuals 
RR of AGW 
incidence 
(crude) 
Woestenberg 2017 
(Netherlands)62 
Bivalent Clinic-based 
PASSYON study in 
STI clinics 
Patients of STI clinics 
aged 16-24 yrs old 
across the Netherlands 
Females and 
males  
16-24 yrs 
2009, 2011, 2013 
Prevaccine: 2009 
Postvaccine: 2011, 2013 
P-yr prevaccine:  
1,662 
P-yr postvaccine: 
3,859 
Clinical diagnosis Proportion of STI 
patients 
diagnosed with 
AGW 
RR of AGW 
proportion 
(adjusted) 
Annual incidence rate of diagnosed AGW in the population 
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Author 
(Country) 
Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect measure 
in publication 
Effect 
measure 
recalculated ß  
Cervical intraepithelial neoplasia grade 2+  
Baldur-Felskov 
2014/2015  
(Denmark) 63, 64 
 
Quadrivalent Population-based: 
Nationwide Danish 
Pathology Data 
Bank 
 
Females aged ≥ 12 yrs 
living in Denmark and 
screened for cervical 
cancer 
 
Screened females  
15-39 yrs 
2007-2013 
Prevaccine:2007-2009 
Postvaccine:2010-2013 
 
P-yr prevaccine: 
1,810,881 
P-yr postvaccine: 
1,840,066 
Histopathologically 
confirmed CIN2+ 
 
Annual 
incidence of 
CIN2+ among 
screened 
females 
RR of CIN2+ 
incidence 
(crude) 
Benard 2017 
(USA)65 
Quadrivalent Population-based: 
New Mexico HPV 
pap registry 
 
Females aged 15-29 yrs 
living in New Mexico 
and screened for cervical 
cancer 
Screened females  
15-29 yrs 
2007-2014 
Prevaccine:2007 
Postvaccine:2008-2014 
P-yr prevaccine: 
74,115 
P-yr postvaccine: 
386,146  
Histopathologically 
confirmed CIN2+ 
Annual 
incidence of 
CIN2+ among 
screened 
females 
RR of CIN2+ 
incidence 
(crude) 
Brotherton 2011/ 
AIHW  2016/2018 
(Australia) § 66-68 
Quadrivalent Population-based: 
Cervical cancer 
screening program 
registry 
Females aged <69 yrs 
living in Australia and 
screened for cervical 
cancer 
Screened females 
15-39 yrs 
2005-2016 
Prevaccine:2005-2007 
Postvaccine:2008-2016 
P-yr prevaccine: 
3,213,016 
P-yr postvaccine: 
9,200,381 
Histopathologically 
confirmed CIN2+ 
 
Annual 
incidence of 
CIN2+ among 
screened 
females 
 
RR of CIN2+ 
incidence 
(crude) 
Flagg 2016 
(USA)69 
Quadrivalent Health provider 
/insurance-based: 
Truven Health 
Analytics Market 
Scan Commercial 
Claims and 
Encounters 
Database 
Females aged 15-39 yrs, 
enrolled in 100-170 
employers and health 
private insurance plans 
across USA and 
screened for cervical 
cancer 
Screened females  
15-39 yrs 
 
2007-2014 
Prevaccine:2007 
Postvaccine:2008-2014 
 
P-yr prevaccine:  
1,542,598 
P-yr postvaccine: 
15,643,924 
Histopathologically 
confirmed CIN2+ 
(ICD-9 code 622.12, 
233.1) 
  
Annual 
prevalence of 
CIN2+ 
among 
screened 
females 
 
RR of CIN2+ 
proportion 
(crude) 
Gargano 2018 
(USA- California, 
Connecticut, New 
York, Oregon, 
Tennessee) 70 
Quadrivalent Population-based: 
HPV-IMPACT 
surveillance system. 
Number of screened 
women estimated 
from different 
sources 
Females aged 18-39 yrs 
with a high-grade lesion 
in HPV-IMPACT (a 
laboratory-based 
surveillance system 
including areas from 
California, Connecticut, 
New York, Oregon, and 
Tennessee) 
Screened females 
18-39 yrs£ 
2008-2015 
Prevaccine:2008 
Postvaccine:2009-2015 
P-yr prevaccine:  
268,186 
P-yr postvaccine: 
1,470,273 
Histopathologically 
confirmed CIN2+ 
 
Annual 
incidence of 
CIN2+ among 
screened 
females 
RR of CIN2+ 
incidence 
(crude) 
Niccolai 2013/2017 
(USA- Connecticut)€ 
71, 72 
Quadrivalent Population-based: 
Connecticut 
surveillance system 
(all 34 pathology 
laboratories). 
Number of screened 
women estimated 
from BRFSS 
Females aged 21-39 yrs 
living in Connecticut 
with a high-grade lesion 
in the surveillance 
system  
Screened females 
20-39 yrs£ 
2008-2014 
Prevaccine:2008 
Postvaccine:2009-2014 
P-yr prevaccine:  
211,134 
P-yr postvaccine: 
643,071 
 
Histopathologically 
confirmed CIN2+ 
 
Annual 
incidence of 
CIN2+ among 
screened 
females  
RR of CIN2+ 
incidence 
(crude) 
Nygård 2017 (via 
Liaw 2014) 
(Norway) 73 Φ 
Quadrivalent Population-based: 
Norwegian cervical 
cancer screening 
program registry 
 
All females living in 
Norway and screened for 
cervical cancer 
 
Screened females 
15-39 yrs 
2007-2014 
Prevaccine:2007-2009 
Postvaccine:2010-2014 
P-yr prevaccine:  
1,262,014 
P-yr postvaccine: 
1,948,739 
Histopathologically  
confirmed CIN2+ 
Annual 
incidence of 
CIN2+ among 
screened 
females 
RR of CIN2+ 
incidence 
(crude) 
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Author 
(Country) 
Vaccine  Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect measure 
in publication 
Effect 
measure 
recalculated ß  
Ogilvie 2015 
(Canada-British 
Columbia) 74 
Quadrivalent Population-based: 
BC Cervical cancer 
screening program 
registry 
Females aged 15-22 yrs 
living in British-
Columbia (Canada) and 
screened for cervical 
cancer 
 
Screened females 
15-17 yrs ¶ 
 
2006-2012 
Prevaccine:2006-2008 
Postvaccine:2009-2012 
P-yr prevaccine:  
27,523 
P-yr postvaccine: 
27,054 
Histopathologically 
confirmed CIN2+ 
Annual 
incidence of 
CIN2+ among 
screened 
females 
RR of CIN2+ 
incidence 
(crude) 
Pollock 2014 
(Scotland) 75 
Bivalent Population-based: 
Scottish Cervical 
cancer screening 
program registry 
Females aged 20-21 yrs 
living in Scotland and 
screened for cervical 
cancer 
Screened females 
20-21 yrs 
2008-2014 
Prevaccine:2008 
Postvaccine:2008-2014 
P-yr prevaccine:  
20,891 
P-yr postvaccine: 
111,230 
Histopathologically 
confirmed CIN2+ 
Annual 
incidence of 
CIN2+ among 
screened 
females 
RR of CIN2+ 
incidence 
(crude) 
 
AGW: Anogenital warts; AIHW: Australian Institute of Health and Welfare; BRFSS: Behavioral Risk Factor Surveillance System; NHANES: National Health and 
Nutrition Examination Survey; NATSAL: National Survey of Sexual Attitudes and Lifestyles; OR: Odds ratio; RR: Relative risk (Post-vaccination prevalence or 
incidence / Pre-vaccination prevalence or incidence); STI: Sexually transmitted infection: GP: General practitioner 
* Data sources are considered as: 1) Population-based when the study population includes the total population of a given country/region or a registry, 2) Health 
provider/insurance-based when the study population is constituted of a subgroup of the total population enrolled in a specific insurance plan, 3) Clinic-based when 
the study population is constituted of individuals who received health services (e.g., medical consultation). 
† For studies on HPV infection, the pre- and post-vaccination periods were already determined in most original publications (except for Kavanagh et al.). For studies 
on AGW and cervical lesions studies, the pre- and post-vaccination periods were determined for the purposes of this systematic review as described in the Appendix- 
Table S8.    
‡ The sample size is restricted to the age groups used in the review. For studies on HPV infection, the pre and post-vaccination sample sizes were already determined 
in original studies. For studies on AGW and cervical lesions, the pre-vaccination sample size corresponds to the cumulative number of person-years up to three years 
pre-vaccination. The post-vaccination sample size corresponds to the cumulative number of person-years from 1 to 8 years after the introduction of vaccination, 
depending on data available in each study. 
ß For HPV infection, the investigators recalculated the RR (adjusted or crude) of prevalence using the original data from their specific studies. For AGW and 
precancerous lesions, we estimated pre-vaccination frequency by aggregating the data for up to three years prior to vaccination, and calculated RR by dividing each 
post-vaccination year by the pre-vaccination estimate. 
** The study by Dillner et al. included data from Denmark, Sweden and Norway among women aged ≥ 18 years in 2012-2013. However , since the vaccination program 
of 12 year-old girls began in 2009 in Norway, women included in the study (≥ 18 years old) were too old to be covered by the vaccination program (vaccination 
coverage < 2%). For this reason, we did not include data from Norway in the meta-analysis.    
Ω Since only oral infections were available for males, we did not include data for males from this study in our meta-analysis. 
γ  The pre-vaccine sample excludes 65 women who were vaccinated (10.6% of the sample). The prevalence of all HPV types, HPV 16/18, and other common HPV 
types did not statistically differ between the vaccinated and unvaccinated women of the pre-vaccination sample (unpublished data). 
Ŧ The study by Machalek includes a subset of women included in the studies by Tabrizi and a group of women aged 25-35 years (not previously included in Tabrizi). 
To avoid double counting the same women, we only kept the results from the older group of women not previously included in Tabrizi. 
‖  13 HR-HPV types were presented in the original publications whereas the 18 HR-HPV types available were used for the purposes of this meta-analysis 
Ψ Published data were available until 2012, but the author provided data up to 2015. 
α  In 2014: 14% and 72% of 15 yr old girls received the quadrivalent and bivalent vaccine, respectively. In 2015, 57% and 29% of 15 yr old girls received the 
quadrivalent and bivalent vaccine, respectively; 14% and 57% of 16 yr old girls received the quadrivalent and bivalent vaccine, respectively. 
24 
 
¥ Permission could not be obtained from the data custodian to release data in the age strata requested for this meta-analysis, therefore results for age groups 15-19, 20-
24, 25-29 and 30-39 years in this meta-analysis used published data from the age groups 12-17, 18-26, 27-30 and 31-69 years, respectively, as reported in Smith 
2015. 58 
§  Data from Brotherton et al. 2011 66 are restricted to the Victorian registry data. Supplementary data from the Australian Institute of Health and Welfare 2016 report 
were provided by Dr. Brotherton. Since the report covers all regions of Australia, it was used as our main data source for the review.   
£ The number of screened women is not directly available in these studies. Different data sources (individual or aggregate-level) have been used to estimate the 
denominator (i.e., the number of screened women of the different catchment areas). 
€ One county from Connecticut (New Haven) is included in the HPV-IMPACT surveillance system. To avoid double counting women from this county in estimates 
from HPV-IMPACT (Gargano 2018) and Connecticut (Niccolai 2017), we decided with the authors, to excluded New Haven from the Connecticut data to keep them 
in HPV-IMPACT.  
Φ  CIN2+ data from Norway were identified in the article by Liaw et al 73 and were provided by Mari Nygård (personal communication) 
¶ Data directly available in the article to estimate RR of CIN2+ incidence among screened females available only for females ages 15-17 years old.
25 
 
Figure 1. Flowchart of study selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 2 articles on anogenital warts from our previous review were not included in this update: 1) Sando et al:104 in our previous 
review, we identified two studies from Denmark analysing the entire Danish population for the same time period,38, 104 We 
included the Baandrup et al. study in our main analysis and verified that results were unchanged when using the Sando et 
al. study. Given that Baandrup et al. updated their data in a new publication, we kept this study with a longer follow-up for 
the current meta-analysis; 2) Nsouli-Maktabi:105 we excluded this study conducted among USA armed force members 
since we revised our eligibility criteria to exclude studies not conducted in the general population. 
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Figure 2. Changes in the prevalence of HPV infections between the pre-vaccination and post-vaccination periods (1-4, 5-8 years) 
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Figure 3. Changes in anogenital wart diagnoses between the pre-vaccination and post-vaccination periods (1-4, 5-8 years) in countries using the quadrivalent 
vaccine 
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Figure 4. Changes in anogenital wart diagnoses during the 8 years after the introduction of girls-only HPV 
vaccination in countries using the quadrivalent vaccine, stratified by number of cohorts vaccinated and routine 
vaccination coverage 
 
A) Girls and women           
 
 
 
 
 
 
 
 
 
 
 
 
B) Boys and men 
   Single-cohort and high-coverage: Canada (Kliewer 2012/Thompson 2016, Guerra 2016), Italy (Cocchio 2017); Multi-
cohort and low coverage: Germany (Mikolajcyk 2013/Thöne 2017), Belgium (Dominiak-Fleden 2015), Sweden (Leval 
2012/Herweijer 2018), USA(Bauer 2012, Flagg 2013/2018) 
 Australia (Ali 2013/Callander 2016, Smith 2015, Harrison 2014, Liu 2014); Denmark (Baandrup 2013/Bollerup 2016); 
New Zealand (Oliphant 2011/2017), Canada (Steben 2018) 
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Figure 5. Changes in CIN2+ among screened girls/women between the pre-vaccination and post-vaccination periods (1-4, 5-9 years) 
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Figure 6. Changes in CIN2+ among screened girls/women during the first 7 years after the introduction of girls-only 
HPV vaccination in countries vaccinating multiple cohorts of girls and having a coverage ≥50% among the routine 
cohort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Australia (Brotherton 2011/AIHW2018), Canada (Ogilvie 2015), Denmark (Baldur-Felskov 2014), Scotland (Pollock 
2014), USA* (Flagg 2016, Niccolai 2017, Gargano 2018, Benard 2017) 
*  For CIN2+ analysis, USA was categorized as a country with multi-cohort vaccination and high routine vaccination 
coverage because several USA data indicate an association between screening participation and HPV vaccination.86, 88, 89, 
91 The vaccination coverage among screened girls/women is thus likely to be higher than the overall vaccination 
coverage in the population. We performed a sensitivity analysis excluding the USA from countries with multi-cohort 
and high vaccination coverage and results were unchanged. 
 
 
 
 
 
 
 
 
 
 
